These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 30095350)

  • 1. Antithrombotic strategies after interventional left atrial appendage closure: an update.
    Chen S; Weise FK; Chun KRJ; Schmidt B
    Expert Rev Cardiovasc Ther; 2018 Sep; 16(9):675-678. PubMed ID: 30095350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity-Matched Comparison of Oral Anticoagulation Versus Antiplatelet Therapy After Left Atrial Appendage Closure With WATCHMAN.
    Søndergaard L; Wong YH; Reddy VY; Boersma LVA; Bergmann MW; Doshi S; Kar S; Sievert H; Wehrenberg S; Stein K; Holmes DR
    JACC Cardiovasc Interv; 2019 Jun; 12(11):1055-1063. PubMed ID: 31171282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DAPT Is Comparable to OAC Following LAAC With WATCHMAN FLX: A National Registry Analysis.
    Coylewright M; Holmes DR; Kapadia SR; Hsu JC; Gibson DN; Freeman JV; Yeh RW; Piccini JP; Price MJ; Allocco DJ; Nair DG
    JACC Cardiovasc Interv; 2023 Nov; 16(22):2708-2718. PubMed ID: 37943200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of percutaneous left atrial appendage closure to prevent thromboembolic events in atrial fibrillation patients with high stroke and bleeding risk.
    Seeger J; Bothner C; Dahme T; Gonska B; Scharnbeck D; Markovic S; Rottbauer W; Wöhrle J
    Clin Res Cardiol; 2016 Mar; 105(3):225-9. PubMed ID: 26318322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Left atrial appendage closure followed by 6 weeks of antithrombotic therapy: a prospective single-center experience.
    Chun KR; Bordignon S; Urban V; Perrotta L; Dugo D; Fürnkranz A; Nowak B; Schmidt B
    Heart Rhythm; 2013 Dec; 10(12):1792-9. PubMed ID: 23973952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology: Final 2-Year Outcome Data of the EWOLUTION Trial Focusing on History of Stroke and Hemorrhage.
    Boersma LV; Ince H; Kische S; Pokushalov E; Schmitz T; Schmidt B; Gori T; Meincke F; Protopopov AV; Betts T; Mazzone P; Foley D; Grygier M; Sievert H; De Potter T; Vireca E; Stein K; Bergmann MW;
    Circ Arrhythm Electrophysiol; 2019 Apr; 12(4):e006841. PubMed ID: 30939908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.
    Ramlawi B; Abu Saleh WK; Edgerton J
    Methodist Debakey Cardiovasc J; 2015; 11(2):100-3. PubMed ID: 26306127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual antiplatelet therapy after percutaneous left atrial appendage occlusion: single center experience with the Amplatzer Cardiac Plug.
    Bertrand PB; Habran M; Kenis K; Lecomte J; Moonen L; Stroobants D; Benit E
    Acta Cardiol; 2019 Feb; 74(1):74-81. PubMed ID: 29607737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Left atrial appendage closure: A therapy uniquely suited for specific populations of patients with atrial fibrillation.
    Black-Maier E; Piccini JP; Granger CB
    J Cardiovasc Electrophysiol; 2019 Dec; 30(12):2968-2976. PubMed ID: 31520437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial Experience With High-Risk Patients Excluded From Clinical Trials: Safety of Short-Term Anticoagulation After Left Atrial Appendage Closure Device.
    Barakat AF; Hussein AA; Saliba WI; Bassiouny M; Tarakji K; Kanj M; Jaber W; Rodriguez LL; Grimm R; Hussain MS; Russman A; Uchino K; Wisco D; Rasmussen P; Bain M; Vargo J; Zuccaro G; Gottesman D; Lindsay BD; Wazni OM
    Circ Arrhythm Electrophysiol; 2016 Jun; 9(6):. PubMed ID: 27225288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of a randomized clinical trial to compare two antithrombotic strategies after left atrial appendage occlusion: double antiplatelet therapy vs. apixaban (ADALA study).
    Flores-Umanzor EJ; Cepas-Guillen PL; Arzamendi D; Cruz-González I; Regueiro A; Freixa X
    J Interv Card Electrophysiol; 2020 Nov; 59(2):471-477. PubMed ID: 32986176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left atrial appendage occluder implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey.
    Tilz RR; Potpara T; Chen J; Dobreanu D; Larsen TB; Haugaa KH; Dagres N
    Europace; 2017 Oct; 19(10):1737-1742. PubMed ID: 29016910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of device-related thrombosis following short-term oral anticoagulation with low-dose dabigatran versus warfarin after Watchman left atrial appendage occlusion.
    Ge H; Zhang C; Qiao ZQ; Hao ZY; Li Z; Gu ZC; Jiang LS; He B; Pu J
    Sci Prog; 2022; 105(3):368504221113194. PubMed ID: 35849447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device.
    Enomoto Y; Gadiyaram VK; Gianni C; Horton RP; Trivedi C; Mohanty S; Di Biase L; Al-Ahmad A; Burkhardt JD; Narula A; Janczyk G; Price MJ; Afzal MR; Atoui M; Earnest M; Swarup V; Doshi SK; van der Zee S; Fisher R; Lakkireddy DR; Gibson DN; Natale A; Reddy VY
    Heart Rhythm; 2017 Jan; 14(1):19-24. PubMed ID: 27771552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of reduced or absent antithrombotic therapy after left atrial appendage closure in patients affected by hereditary hemorrhagic telangiectasia and atrial fibrillation.
    Pepe M; Suppressa P; Giuliano AF; Nestola PL; Bortone AS; DE Cillis E; Acquaviva T; Forleo C; Moscarelli M; Lenato GM; Sabbà C
    Minerva Cardiol Angiol; 2022 Oct; 70(5):537-544. PubMed ID: 33703853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Best anticoagulation strategy with and without appendage occlusion for stroke-prophylaxis in postablation atrial fibrillation patients with cardiac amyloidosis.
    Mohanty S; Torlapati PG; La Fazia VM; Kurt M; Gianni C; MacDonald B; Mayedo A; Allison J; Bassiouny M; Gallinghouse GJ; Burkhardt JD; Horton R; Di Biase L; Al-Ahmad A; Natale A
    J Cardiovasc Electrophysiol; 2024 Jul; 35(7):1422-1428. PubMed ID: 38751010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Left atrial appendage closure.
    Lin AC; Knight BP
    Prog Cardiovasc Dis; 2015; 58(2):195-201. PubMed ID: 26241302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials.
    Friedman DJ; Du C; Wang Y; Agarwal V; Varosy PD; Masoudi FA; Holmes DR; Reddy VY; Price MJ; Curtis JP; Freeman JV
    JACC Cardiovasc Interv; 2022 May; 15(9):950-961. PubMed ID: 35512918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombotic therapy after left atrial appendage closure.
    Schmidt B; Chun KR
    Expert Rev Cardiovasc Ther; 2015 Jan; 13(1):105-9. PubMed ID: 25434598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous left atrial appendage occlusion: A review of current devices, clinical evidence, patient selection, and post procedural antithrombotic management.
    Jackson LR; Jackson KP; Thomas KL
    Prog Cardiovasc Dis; 2021; 66():92-100. PubMed ID: 34332665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.